Quantcast

Industry news that matters to you.  Learn more

Archives for June 2015

DNAnexus Cloud Genomics Platform to Support Data Management and Genomic Analysis for a Global Research Consortium

DNAnexus Inc., the leader in cloud-based genome informatics and data management, today announced that Stanford University, the Data Coordination Center (DCC) for the National Institutes of Health (NIH)-funded ENCyclopedia of DNA Elements (ENCODE) Project, a flagship functional genomics consortium funded by the National Human Genome Research Institute (NHGRI) at the NIH, has adopted the company’s cloud genomics platform to support data analysis and sharing for its Phase 3 project. The DNAnexus platform supports the DCC bioinformatics analysis of ENCODE data, making the consortium’s bioinformatics methods available to the broader research community.

Swedish Cancer Institute Elevates Personalized Medicine Program with Innovative Software Platform

The Swedish Cancer Institute (SCI), one of the Northwest’s leading cancer treatment centers, recently announced the adoption of Syapse Precision Medicine Platform to enhance its Personalized Medicine Program. The innovative software platform will enable clinicians to better integrate genomic information into patient care and move critical cancer research forward.

Rosetta Genomics Receives Key U.S. Patent Allowance for its Cancer of Origin Diagnostic Assay

Rosetta Genomics Ltd. (NASDAQ: ROSG), a leading developer and provider of microRNA-based assays, FISH testing and other molecular diagnostics, announces receipt of a Notice of Allowance for U.S. Patent Application No. 13/856,190, entitled, “Methods and materials for classification of tissue of origin of tumor samples.”

Roche To Develop Companion Diagnostic Test For Acute Coronary Syndrome

Roche (SIX: RO, ROG; OTCQX: RHHBY) recently announced it has entered into an agreement to develop a companion diagnostic (CDx) test for dalcetrapib, a therapeutic from DalCor Pharmaceuticals (DalCor), which will target patients with a specific genotype who have experienced a recent Acute Coronary Syndrome (ACS) event. The CDx test from Roche will be used in a phase III clinical trial that will seek to validate the clinical efficacy of dalcetrapib, an investigational medicine that according to a recently published analysis by the Montreal Heart Institute, could potentially reduce cardiovascular morbidity and mortality by as much as 39 percent in patients with a specific genetic profile.

Flagship Biosciences and Advanced Cell Diagnostics Collaborate to Develop Quantitative RNAscope Assays for Pharmaceutical Clinical Trials in the CLIA Environment

Flagship Biosciences, the leading service provider of tissue image analysis solutions, recently announced the utilization of its wet assay development and image analysis quantification capabilities for RNAscope® RNA in situ hybridization (ISH) from Advanced Cell Diagnostics, Inc. (ACD), a technology and market leader in the field of molecular pathology and developer of cell and tissue-based analysis tools. The two companies will work to optimize quantitative image analysis of in situ hybridization in tissue samples in Flagship’s CLIA laboratory.